Cytori Therapeutics Inc. (CYTX)

0.28
NASDAQ : Health Technology
Prev Close 0.28
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.21 / 1.21
Avg Volume 1.08M
Exchange NASDAQ
Shares Outstanding 61.61M
Market Cap 16.82M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytori Reports Reduction In Fibrosis Parameters In Scar Study

Cytori Reports Reduction In Fibrosis Parameters In Scar Study

BARDA Funded Preclinical Published in Stem Cell Research and Therapy

Cytori Announces New U.S. Investigator Trial For Hip Osteonecrosis

Cytori Announces New U.S. Investigator Trial For Hip Osteonecrosis

Updates on Other Selected Global Investigator Initiated Trials

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

A number of biotech-related stocks were down pre-market after announcing plans for public offerings.

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.

Cytori® Partners With MyTomorrows For Managed Access Program For Europe, Middle East And Latin America

Partnership to Launch at the EULAR (European League Against Rheumatism) Congress in Madrid, Spain June 14-17

Cytori Logs Final 48 Week Patient Follow Up Visit In Scleroderma Trial

Topline trial results announcement expected early Q3 2017

Cytori Provides Latest Corporate Update At The 18th Annual B. Riley & Co. Institutional Investor Conference

Presentation on Wednesday, May 24, 2017 at 09:00 AM Pacific Time

TheStreet Quant Rating: D- (Sell)